Malcolm Spicer, Managing Editor – US
Latest From Malcolm Spicer
ODS Director Steven Tave says violative manufacturing processes and products remain common not because FDA isn’t enforcing its regulations. “I applaud those who stand behind their products, but can you stand with the same conviction behind every product on the market?” he said at regulatory summit organized by trade groups.
"Because of what a lot of consumers are facing right now, layoffs, furloughs, working online, they may not be aware of how this health savings account benefit can serve them at this time,” says Finance Bar CEO Marsha Barnes. CHPA is preparing digital campaign to explain that health savings, flexible spending and similar pre-tax accounts once again can be used for direct purchases of OTC drugs.
Deadline passed for “other qualified bidders to submit higher or otherwise better offers to purchase” full ownership of GNC. Approving sale to Harbin Pharmaceuticals, already its largest shareholder, depends partly on approval by US bankruptcy court, where a hearing is set for 17 September.
FTC Division of Advertising Practices anticipated surge of false ads for consumer health products related to COVID-19 but it didn’t expect quite the number as well as the variety of bogus claims it’s found, says Assistant Director Richard Cleland.
DynamicVetnures also contends Harbin Pharmaceutical is attempting to avoid a regulatory review by federal agencies on national security and other questions that is required when foreign companies make large investments in US businesses.
House Energy and Commerce members are expected soon to introduce a bill to make lawful the use of CBD and other hemp-derived ingredients, other than THC, in dietary supplements. Capitol Hill interest in proposing legislation, says Sen. Wyden , will grow if FDA doesn’t bring some order to the CBD space.